Immunoglobulin E monitoring and reduction of omalizumab therapy in children and adolescents

Allergy and Asthma Proceedings

Volumn 33, Issue 1, 2012, Pages 77-81

  Steiß, Jens Oliver ^a   Schmidt, Annesuse ^a   Nährlich, Lutz ^a   Zimmer, Klaus Peter ^a   Rudloff, Silvia ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; OMALIZUMAB;

ADOLESCENT; ADOLESCENT DISEASE; ALLERGIC ASTHMA; ARTICLE; ATOPIC DERMATITIS; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INSECT ALLERGY; LUNG FUNCTION TEST; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; PEAK EXPIRATORY FLOW; PEANUT ALLERGY; QUALITY OF LIFE; RHINOCONJUNCTIVITIS; SCHOOL CHILD;

ADOLESCENT; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CHILD; DISEASE PROGRESSION; DRUG DOSAGE CALCULATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN E; MALE; MONITORING, IMMUNOLOGIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84857468722     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2012.33.3500     Document Type: Article

References (23)

1. Gould HJ, and Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol 8:205-217, 2008. (Pubitemid 351323292)
2. Hogate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 115:459-465, 2005. (Pubitemid 40341694)
3. Ledford DK. Omalizumab: Overview of pharmacology and efficacy in asthma. Expert Opin Biol Ther 9:933-943, 2009.
4. Long AA. Immunomodulators in the treatment of asthma. Allergy Asthma Proc 30:109-119, 2009.
5. Hamilton RG, Marcotte GV, and Saini SS. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving Omalizumab (Xolair) therapy. J Immunol Methods 303:81-91, 2005. (Pubitemid 41169948)
6. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 202 step 4 treatment): INNOVATE. Allergy 60:305-316, 2005.
7. Humbert M, Lowe P, and Ferioli C. Returning asthma symptoms correlate with free IgE upon omalizumab cessation. Eur Respir J 30(suppl 51):620s-621s, P3639, 2007.
8. Slavin R, Ferioli C, Tannenbaum S, et al. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol 123:107-113, 2009.
9. Kwong KY, and Jones CA. Improvement of asthma control with omalizumab in 2 obese pediatric asthma patients. Ann Allergy Asthma Immunol 97:288-293, 2006. (Pubitemid 44476562)
10. Lane JE, Ceyney JM, Lane TN, et al. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 54:68-72, 2006. (Pubitemid 41832460)
11. van der Ent CK, Hoekstr H, and Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 62:267-277, 2007.
12. Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 101:1483-1492, 2007. (Pubitemid 46850589)
13. Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 124:1210-1216, 2009.
14. Soler M, J Matz, R Townley, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18:254-261, 2001. (Pubitemid 32776398)
15. Genentech, Inc. Omalizumab. Xolair full prescribing information J2. San Francisco, CA; 2009. Available online at www.gene.com/gene/products/information/ immunological/xolair/insert.jsp; accessed July, 2010.
16. Hochhaus G, Brookman L, Fox H, et al. Pharmacodynamics of omalizumab: Implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 19:491-498, 2003. (Pubitemid 37122042)
17. Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 206:253-259, 2000. (Pubitemid 30644998)
18. Casale TB, Bernstein IL, Busse WW, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 100:110-112, 1997.
19. Strohner P, Sarrach D, Reich JG, et al. The recovery-ELISA - A novel assay technique for the therapy control of therapeutic antibodies. Am J Respir Crit Care Med 181:A5674, 2010.
20. Steiß JO, Strohner P, Zimmer KP, et al. Reduction of the total IgE level by omalizumab in children and adolescents. J Asthma 45:233-236, 2008. (Pubitemid 351549802)
21. Lowe P, Tannenbaum S, Gautier A, et al. Omalizumab (Xolair) may normalize IgE production rate in patients with moderate-zo-severe atopic asthma. J Allergy Clin Immunol 123(suppl 1):S152, 2009.
22. Hanf G, Brachmann I, Kleine-Tebbe J, et al. Omalizumab decreased IgE-release and induced changes in cellular immunity in patients with allergic asthma. Allergy 61:1141-1144, 2007. (Pubitemid 44175224)
23. Nopp A, Johansson SGO, Adedoyin J, et al. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy 65:56-60, 2010.